Sequent Scientific Limited (SEQUENT.NS) NSE
Currency In INR
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In INR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1195
First IPO Date
March 10, 2016
| Name | Title | Pay | Year Born |
| Rajaram Narayanan | MD, Chief Executive Officer & Director | 19.87M | 1968 |
| Yoshita Vora | Company Secretary & Compliance Officer | 3.13M | N/A |
| Phillip Trott | Assoc. Vice President, Head of Legal & Chief Risk Officer | 7.66M | N/A |
| Ramakant Singani | Chief Financial Officer | 15.36M | N/A |
| Saurav Bhala | Chief Financial Officer | 15.36M | N/A |
| Abhishek Singhal | Head of Investor Relations | 0 | N/A |
| Prasad Lad | Vice President of HR & Administration | 0 | N/A |
| Ramesh Kumar Pillai | Corporate Vice President of Ra Qa and Technical Services | 0 | 1965 |
| Ravi Nair | Executive Vice President of Human Resources & Administration | 0 | N/A |
Operating on a global scale, Sequent Scientific Limited specializes in the animal health sector. The company supplies both active pharmaceutical ingredients (APIs) and formulated products for animals, addressing a diverse range of therapeutic needs. These offerings encompass anthelmintics (including treatments for internal and external parasitic infections), anti-protozoal agents, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives, and dermatological solutions. Furthermore, Sequent Scientific provides extensive analytical services that support organizations across the API, pharmaceutical, personal care, and nutraceutical industries. These services feature method validation, stability assessments, and microbiological testing for both active ingredients and final products. Established in 1985 and headquartered in Mumbai, India, the firm was previously known as PI Drugs and Pharmaceuticals Limited and currently operates as a subsidiary of CA Harbor Investments.